Jan 30, 20211 minTAGRISSO in the Treatment of Resectable NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R MutationsThis 60-minute program includes a presentation and a question-and-answer session about the adjuvant treatment of resectable EGFR...
Jan 30, 20211 minA program on an FDA-approved treatment option metastatic Urothelial Carcinoma ~ PADCEVPRESENTED BY Daniel Landau, MD Section Chief Hematology/Oncology Orlando Health UF Health Cancer Center Orlando, FL DATE AND TIME...
Jan 28, 20211 minPatient Access Services and Reimbursement OverviewOBJECTIVES: - Describe the patient access services available through Coherus COMPLETE. - Explain coding and the coverage and...
Jan 16, 20211 minImpact of Long-Term Echelon-1 Data in Stage III/IV CHLThursday, January 21st, 2021 6:30PM and 9:00PM Sponsored by Seagen For more information visit the following link:...
Jan 7, 20211 minTAZVERIK (tazemetostat) ~ Relapsed or Refractory Follicular LymphomaDon't miss this new upcoming event! Click image above to register! Event flyer attached below.
Dec 6, 20201 minTAZVERIK ~ Now Approved ~ Virtual Talk Thursday, 12/10/20 @ 5:00PMTAZVERIK™ (tazemetostat) is indicated for the treatment of:∙Adult patients with relapsed or refractory follicular lymphoma whose tumors...